Chinese Journal of Experimental Traditional Medical Formulae
Preparation and Anti-tumor Activity Investigation of Combretastatin A-4P Nanoparticles Encapsulated with PLGA
Author:
Affiliation:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
    Abstract:

    Objective: To prepare combretastatin A-4P(CA4P) sustained release nanoparticles with polylactic acid-polyglycolic acid(PLGA) as carrier material,and investigate its in vitro and in vivo anti-tumor activity. Method: CA4P-PLGA-NPs were made by W/O/W double emulsion solvent evaporation method,morphology of CA4P-PLGA-NPs was observed by transmission electron microscopy,particle size distribution was measured by dynamic laser scattering instrument,drug loading,encapsulation efficiency and in vitro cumulative release rate were determined by HPLC.In vitro cytotoxic activity of CA4P-PLGA-NPs on Hela cell was measured by MTT assay,in vivo antitumor activity was evaluated by tumor-bearing nude mice test. Result: Particle size distribution of CA4P-PLGA-NPs was narrow with average particle size was 113.7 nm,average drug loading was (12.5±0.8)%,average encapsulation efficiency was (58.9±1.2)%,these data showed that CA4P-PLGA-NPs had a certain sustained-release effect.CA4P-PLGA-NPs had good in vitro and in vivo anti-tumor activity through MTT and tumor-bearing nude mice test. Conclusion: CA4P-PLGA-NPs prepared by W/O/W solvent evaporation method had sustained-release effect,its anti-tumor activity was better than CA4P.

    Reference
    Related
    Cited by
Get Citation
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:November 06,2012
  • Revised:
  • Adopted:
  • Online: April 12,2013
  • Published:

Address:

Postcode:100700

Phone:010-84076882

E-mail:syfjx_2010@188.com

® 2024 All Rights Reserved

Supported by:Beijing E-Tiller Technology Development Co., Ltd.